KR102307601B1 - 즉시 사용가능한 케토로락 제제 - Google Patents

즉시 사용가능한 케토로락 제제 Download PDF

Info

Publication number
KR102307601B1
KR102307601B1 KR1020207013936A KR20207013936A KR102307601B1 KR 102307601 B1 KR102307601 B1 KR 102307601B1 KR 1020207013936 A KR1020207013936 A KR 1020207013936A KR 20207013936 A KR20207013936 A KR 20207013936A KR 102307601 B1 KR102307601 B1 KR 102307601B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutical composition
ketorolac
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013936A
Other languages
English (en)
Korean (ko)
Other versions
KR20200078541A (ko
Inventor
조셉 페르골리지
알렉산더 미로노프
차드 제임스 피켄즈
더글라스 자일스 존슨
Original Assignee
알티유 파머수티컬즈, 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알티유 파머수티컬즈, 엘엘시 filed Critical 알티유 파머수티컬즈, 엘엘시
Publication of KR20200078541A publication Critical patent/KR20200078541A/ko
Application granted granted Critical
Publication of KR102307601B1 publication Critical patent/KR102307601B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020207013936A 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제 Active KR102307601B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40538410P 2010-10-21 2010-10-21
US61/405,384 2010-10-21
US201161481602P 2011-05-02 2011-05-02
US61/481,602 2011-05-02
PCT/US2011/057284 WO2012054831A2 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations
KR1020187027505A KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187027505A Division KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Publications (2)

Publication Number Publication Date
KR20200078541A KR20200078541A (ko) 2020-07-01
KR102307601B1 true KR102307601B1 (ko) 2021-09-30

Family

ID=45973506

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187027505A Active KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020197019855A Ceased KR20190085561A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020137009935A Ceased KR20140012029A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020207013936A Active KR102307601B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020187027505A Active KR102114568B1 (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020197019855A Ceased KR20190085561A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제
KR1020137009935A Ceased KR20140012029A (ko) 2010-10-21 2011-10-21 즉시 사용가능한 케토로락 제제

Country Status (19)

Country Link
US (5) US9421191B2 (enExample)
EP (3) EP3632432B1 (enExample)
JP (1) JP6013346B2 (enExample)
KR (4) KR102114568B1 (enExample)
CN (2) CN108703948A (enExample)
CA (1) CA2814805C (enExample)
CY (1) CY1122516T1 (enExample)
DK (1) DK2616064T3 (enExample)
ES (2) ES2753981T3 (enExample)
HR (1) HRP20191994T1 (enExample)
HU (1) HUE045889T2 (enExample)
LT (1) LT2616064T (enExample)
MX (1) MX346879B (enExample)
PL (1) PL2616064T3 (enExample)
PT (1) PT2616064T (enExample)
RS (1) RS59526B1 (enExample)
SI (1) SI2616064T1 (enExample)
SM (1) SMT201900656T1 (enExample)
WO (1) WO2012054831A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2753981T3 (es) 2010-10-21 2020-04-15 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para uso
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992485B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US10098872B1 (en) 2013-07-22 2018-10-16 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103830171B (zh) * 2014-03-04 2015-11-18 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
JP6746612B2 (ja) * 2015-11-25 2020-08-26 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含む医薬組成物
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
KR20240094040A (ko) * 2017-05-10 2024-06-24 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
FR3101917B1 (fr) 2019-10-09 2022-07-15 Ifp Energies Now Système de refroidissement à radiateur unique
CN110812325B (zh) * 2019-11-13 2022-04-05 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
CN113679676A (zh) * 2020-05-19 2021-11-23 南京海融医药科技股份有限公司 一种左酮咯酸的药物组合物及其制备方法
CN114159384B (zh) * 2021-02-07 2023-04-07 南京锐志生物医药有限公司 一种化学性质稳定的低刺激性酮咯酸氨丁三醇注射液
US20240325303A1 (en) * 2021-06-24 2024-10-03 Shanghai Aurora Biotechnology Co., Ltd. Ketorolac liquid composition, preparation method therefor, and application thereof
CN113384524B (zh) * 2021-07-05 2025-08-12 四川尚锐生物医药有限公司 一种稳定的酮咯酸氨丁三醇注射液的制备方法
CN114191384A (zh) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂
CN114432240A (zh) * 2022-03-04 2022-05-06 郑州市中心医院 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
ATE268178T1 (de) 1997-07-11 2004-06-15 Toray Industries Stabile medizinische zusammenstellungen die 4,5- epoxymorphinanderivate enthalten
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
EE200100500A (et) 1999-03-26 2003-02-17 Pozen Inc. Suure võimsusega dihüdroergotamiini kompositsioonid
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080317681A1 (en) 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DE602005027727D1 (de) 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
EP1948133B1 (en) 2005-09-01 2011-06-29 BAXTER INTERNATIONAL INC. (a Delaware corporation) Argatroban formulation comprising an acid as solubilizer
US20070142478A1 (en) * 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
DOP2007000055A (es) 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
US20070244166A1 (en) 2006-04-18 2007-10-18 Pdl Biopharma, Inc. Pre-mixed, ready-to-use iv bolus compositions and methods of use
US20100010046A1 (en) 2006-06-12 2010-01-14 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
WO2008005267A2 (en) 2006-06-29 2008-01-10 Schering Corporation Sugar-free storage-stable antihistaminic syrups
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080057023A1 (en) 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
US7589106B2 (en) 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
KR100836624B1 (ko) 2006-12-08 2008-06-10 한국전자통신연구원 가변 고속 푸리에 변환 장치 및 그 방법
US20080312154A1 (en) 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
DK2197429T3 (en) 2007-09-03 2016-05-30 Nanotherapeutics Inc Particulate compositions for delivery of poorly soluble drugs
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
US20090239836A1 (en) 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8956636B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TWI397038B (zh) * 2008-11-05 2013-05-21 Au Optronics Corp 使用半源極驅動架構之顯示面板及其顯示資料供應方法
KR20190031592A (ko) * 2010-07-19 2019-03-26 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
US8722738B2 (en) 2010-07-21 2014-05-13 Cumberland Pharmaceuticals, Inc. Acetycysteine compositions and methods of use thereof
ES2753981T3 (es) 2010-10-21 2020-04-15 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration

Also Published As

Publication number Publication date
US20190105301A1 (en) 2019-04-11
PT2616064T (pt) 2019-11-06
US11116750B2 (en) 2021-09-14
PL2616064T3 (pl) 2020-02-28
US20180280351A1 (en) 2018-10-04
ES2753981T3 (es) 2020-04-15
CY1122516T1 (el) 2021-01-27
SI2616064T1 (sl) 2019-12-31
DK2616064T3 (da) 2019-11-11
CN108703948A (zh) 2018-10-26
JP2013543843A (ja) 2013-12-09
KR20140012029A (ko) 2014-01-29
US20220023260A1 (en) 2022-01-27
US20120101142A1 (en) 2012-04-26
HRP20191994T1 (hr) 2020-02-07
CA2814805C (en) 2021-11-02
SMT201900656T1 (it) 2020-01-14
US9962371B2 (en) 2018-05-08
JP6013346B2 (ja) 2016-10-25
KR20180119610A (ko) 2018-11-02
LT2616064T (lt) 2019-11-25
CA2814805A1 (en) 2012-04-26
KR20190085561A (ko) 2019-07-18
US9421191B2 (en) 2016-08-23
HUE045889T2 (hu) 2020-01-28
EP4190327A1 (en) 2023-06-07
KR20200078541A (ko) 2020-07-01
EP2616064A2 (en) 2013-07-24
RS59526B1 (sr) 2019-12-31
WO2012054831A3 (en) 2012-06-07
MX346879B (es) 2017-04-03
EP2616064A4 (en) 2016-07-20
EP2616064B1 (en) 2019-08-07
MX2013004393A (es) 2014-09-12
US20170007575A1 (en) 2017-01-12
EP3632432B1 (en) 2022-09-14
WO2012054831A2 (en) 2012-04-26
ES2933198T3 (es) 2023-02-02
EP3632432A1 (en) 2020-04-08
KR102114568B1 (ko) 2020-05-22
US10278959B2 (en) 2019-05-07
CN103167800A (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
KR102307601B1 (ko) 즉시 사용가능한 케토로락 제제
US10517864B2 (en) Sustained-release buprenorphine solutions
TWI844703B (zh) 穩定的ast-3424注射液製劑及製備方法
EP2683361B1 (en) Method for the preparaton of a levothyroxine solution
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
AU2004268602A2 (en) Intranasal opioid compositions
CA2677281A1 (en) Transoral dosage forms comprising sufentanil and naloxone
AU2015289035A1 (en) Aqueous formulation comprising paracetamol and ibuprofen
HK40026993B (en) Ready to use ketorolac formulations
HK40026993A (en) Ready to use ketorolac formulations
HK1262803A1 (en) Ready to use ketorolac formulations
US11446311B2 (en) Methods for treating pain associated with sickle cell disease
WO2007022609A1 (en) Pharmaceutical composition of morphine in ready-to-use injectable solution form and single dosage form of morphine for epidural or intrathecal administration
WO2014083071A1 (en) Injectable liquid formulation of the combination of tramadol and paracetamol

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5